Drugs / NB-001
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07577050 | Apr → Sep 2026 overdue | migraine disorder | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05290493 | Feb 2022 → Jun 2023 | syndrome caused by partial chromosomal deletion | Nobias Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00453401 | Feb → Dec 2007 | herpes labialis | NanoBio Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01695187 | Oct 2012 → Jun 2013 | herpes labialis | NanoBio Corporation | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01321359 Comparator | Apr 2011 → Jan 2012 | herpes labialis | NanoBio Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01324466 Comparator | Apr 2011 → Jan 2012 | herpes labialis | NanoBio Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01324466 ↗ |
| Known as | HTS-09836 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297305 ↗ |
| Modality | Other / unclassified | “NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm).” NCT01695187 ↗ |
| Route | Topical | “topical applications of NB-001” NCT00453401 ↗ |